APEN - Apollo Endosurgery, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Apollo Endosurgery, Inc.

1120 South Capital of Texas Highway
Building 1 Suite 300
Austin, TX 78746
United States

IndustryMedical Devices
Full Time Employees217

Key Executives

NameTitlePayExercisedYear Born
Mr. Todd NewtonCEO & Director546.1kN/A1963
Ms. Stefanie L. CavanaughCFO, Treasurer & Sec.356.73kN/A1965
Mr. Bret SchwartzhoffVP, US Sales & Global Marketing343kN/A1973
Dr. Sergey Kantsevoy M.D.Co-Founder and Innovation PartnerN/AN/AN/A
Mr. Anthony Kalloo M.D.Co-Founder and Innovation PartnerN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. Its products include OverStitch and OverStitch Sx Endoscopic Suturing System that enables advanced endoscopic procedures by allowing physicians to place full thickness sutures and secure the approximation of tissue through a flexible endoscope; Orbera365 Managed Weight Loss System; and the BIB for the treatment of overweight and obese adults. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Brazil, Australia, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.

Corporate Governance

Apollo Endosurgery, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.